Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency

Figure 1 Effects of pancreatic enzyme replacement therapy on body weight in children with cystic fibrosis and pancreatic exocrine insufficiency. A: Age-adjusted z-scores¹ for length and weight at baseline and after 8 wk of pancreatic enzyme replacement therapy (PERT) in children < 2 years of age[27]; B: mean change from baseline after 12 wk of PERT in age-adjusted z-scores¹ for length and weight in children 1 mo to < 4 years of age[28]. ¹Z-scores are commonly used to assess growth percentiles and compare patients of different ages and at different rates of growth. It indicates the number of standard deviation away from the mean. ^aP < 0.05. PERT: Pancreatic enzyme replacement therapy; SD: Standard deviation.